Briacell Therapeutics Corp's stock has seen a decline this week amid significant company developments.
Briacell Therapeutics Corp (BCT.TO) has had a tough week, with its stock price dropping by 3.64% on Monday and 4.37% over the past week. Despite this downturn, the stock has gained 16.98% over the last month. Investors may want to understand the recent company news that could be influencing these movements.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$43.76M
52W high
$20.40
52W low
$3.68
1W change
-4.37%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 297.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+297.6% Upside
Current Price
C$5.03
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
57.4%
Annualized
90-Day Vol
83.2%
Annualized
Trend (90d)
-37.5%
Annualized drift
90d Mean
C$4.40
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$4.81 | C$3.95 โ C$5.86 |
| 60 trading days | C$4.60 | C$3.48 โ C$6.09 |
| 90 trading days | C$4.40 | C$3.12 โ C$6.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Briacell's recent announcements about its clinical trials and manufacturing capabilities could have long-term effects on its stock performance. However, current technical indicators suggest caution since the stock remains significantly below its 200-day moving average.
Briacell's Stock Down 3.64% Today, But Up 16.98% in the Last Month.
Despite a recent uptick, Briacell's stock is still down 48.78% year-to-date, indicating volatility and uncertainty in its performance.
Bull case
Analysts maintain a bullish outlook, with an average target price of C$20.00. This suggests strong potential for recovery if Briacell successfully advances its clinical trials and scales its manufacturing capabilities.
Bear case
On the flip side, the stock's significant year-to-date decline and negative return on equity raise concerns about the company's financial health and its ability to deliver in a competitive healthcare sector.
Recent Company News
Briacell Therapeutics has made headlines this week with the opening of its first Canadian site at Sunnybrook for a pivotal Phase 3 trial targeting metastatic breast cancer. This trial is crucial for the company's Bria-IMTโข treatment, which aims to improve patient outcomes. Additionally, Briacell has arranged scalable manufacturing with FUJIFILM Biotechnologies, enhancing its ability to produce innovative therapies as demand grows.
Technical Picture
As of the last close, Briacell's stock is trading at C$5.03, which is above its 50-day moving average of C$4.70 but significantly below its 200-day moving average of C$8.22. The stock has a beta of 1.54, indicating higher volatility compared to the broader market. The 52-week range of C$3.68 to C$20.40 shows that the stock is currently at 8% of its range. With a volume of 1,015 shares against a 20-day average of 6,841 shares, the trading activity suggests subdued interest from investors.
Insider Activity
There are no recent insider trading activities reported for Briacell Therapeutics Corp, indicating that insiders may not be making significant moves at this time.
Price Action
Briacell Therapeutics Corp (BCT.TO) closed at C$5.03 on Monday, reflecting a 1-day decline of 3.64%. The stock has experienced a weekly decrease of 4.37%, highlighting ongoing challenges despite recent positive developments.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
